89 related articles for article (PubMed ID: 21447603)
1. Calcineurin subunit B activates dendritic cells and acts as a cancer vaccine adjuvant.
Li J; Guo J; Su Z; Hu M; Liu W; Wei Q
Int Immunol; 2011 May; 23(5):327-34. PubMed ID: 21447603
[TBL] [Abstract][Full Text] [Related]
2. Ginsenoside Rg1 Activates Dendritic Cells and Acts as a Vaccine Adjuvant Inducing Protective Cellular Responses Against Lymphomas.
Huang Y; Zou Y; Lin L; Zheng R
DNA Cell Biol; 2017 Dec; 36(12):1168-1177. PubMed ID: 29058460
[TBL] [Abstract][Full Text] [Related]
3. Calcineurin B subunit triggers innate immunity and acts as a novel Engerix-B HBV vaccine adjuvant.
Hu M; Su Z; Yin Y; Li J; Wei Q
Vaccine; 2012 Jul; 30(32):4719-27. PubMed ID: 22652401
[TBL] [Abstract][Full Text] [Related]
4. Nontoxic Shiga toxin derivatives from Escherichia coli possess adjuvant activity for the augmentation of antigen-specific immune responses via dendritic cell activation.
Ohmura M; Yamamoto M; Tomiyama-Miyaji C; Yuki Y; Takeda Y; Kiyono H
Infect Immun; 2005 Jul; 73(7):4088-97. PubMed ID: 15972497
[TBL] [Abstract][Full Text] [Related]
5. [Dendritic cells present particulate E7 protein of human papillomavirus and induce strong immunity].
Li J; Gao HQ; Zhao CL; Li LZ; Ji CY; Hou M; Plebaski M
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):932-6. PubMed ID: 15329282
[TBL] [Abstract][Full Text] [Related]
6. Calcineurin subunit B is an immunostimulatory protein and acts as a vaccine adjuvant inducing protective cellular and humoral responses against pneumococcal infection.
Li J; Hu M; Guo J; Su Z; Wei Q
Immunol Lett; 2011 Oct; 140(1-2):52-8. PubMed ID: 21722668
[TBL] [Abstract][Full Text] [Related]
7. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
8. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo.
Porgador A; Staats HF; Faiola B; Gilboa E; Palker TJ
J Immunol; 1997 Jan; 158(2):834-41. PubMed ID: 8993001
[TBL] [Abstract][Full Text] [Related]
9. Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity.
Kojima N; Biao L; Nakayama T; Ishii M; Ikehara Y; Tsujimura K
J Control Release; 2008 Jul; 129(1):26-32. PubMed ID: 18485512
[TBL] [Abstract][Full Text] [Related]
10. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel acts as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice.
Yuan L; Wu L; Chen J; Wu Q; Hu S
Vaccine; 2010 Jun; 28(27):4402-10. PubMed ID: 20434553
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidylinositol mannosides are efficient mucosal adjuvants.
Parlane NA; Denis M; Severn WB; Skinner MA; Painter GF; La Flamme AC; Ainge GD; Larsen DS; Buddle BM
Immunol Invest; 2008; 37(2):129-42. PubMed ID: 18300038
[TBL] [Abstract][Full Text] [Related]
13. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
[TBL] [Abstract][Full Text] [Related]
14. The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling.
Met O; Wang M; Pedersen AE; Nissen MH; Buus S; Claesson MH
Cancer Lett; 2006 Jan; 231(2):247-56. PubMed ID: 16399226
[TBL] [Abstract][Full Text] [Related]
15. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
16. [Immunological efficiency of DNA vaccine targeting dendritic cells against tumor].
Zhu B; Cheng XM; Duan YZ; Guo B; Wu YZ; Chen ZT
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Mar; 22(2):239-42. PubMed ID: 16507263
[TBL] [Abstract][Full Text] [Related]
17. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines.
Okada H; Tsugawa T; Sato H; Kuwashima N; Gambotto A; Okada K; Dusak JE; Fellows-Mayle WK; Papworth GD; Watkins SC; Chambers WH; Potter DM; Storkus WJ; Pollack IF
Cancer Res; 2004 Aug; 64(16):5830-8. PubMed ID: 15313927
[TBL] [Abstract][Full Text] [Related]
18. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
19. Immunological responses after immunisation of mice with microparticles containing antigen and single stranded RNA (polyuridylic acid).
Westwood A; Elvin SJ; Healey GD; Williamson ED; Eyles JE
Vaccine; 2006 Mar; 24(11):1736-43. PubMed ID: 16278038
[TBL] [Abstract][Full Text] [Related]
20. Induction of antitumor immunity using bone marrow-generated dendritic cells.
Porgador A; Snyder D; Gilboa E
J Immunol; 1996 Apr; 156(8):2918-26. PubMed ID: 8609412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
